TCF3

Across TCGA pan-cancer cohorts, TCF3 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TCF3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where TCF3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TCF3 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LUAD, HNSC, and LSCC are the cancer types where TCF3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TCF3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	+0.726	<.001	9	view →
HNSC	Male	IV	+0.923	<.001	8	view →
LSCC	Male	All	+0.923	<.001	8	view →
PDAC	Male	All	−0.410	.002	4	view →
CCRCC	Male	All	+0.199	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TCF3–LUAD

Open the LUAD breakdown →